Avant Immunotherapeutics

79 articles about Avant Immunotherapeutics

• Ology Bioservices Strengthens Management Team with Addition of Timothy Cooke, Ph.D. as Senior Vice President of Commercial Business

  10/17/2018

  Ology Bioservices, Inc. announced today that industry veteran Timothy Cooke, Ph.D., has joined the Company as Senior Vice President of Commercial Business.

• Avant Immunotherapeutics Announces Name Change to Celldex Therapeutics, Inc.; Anthony S. Marucci Appointed President and CEO

  9/29/2008

• Avant Immunotherapeutics CEO To Present at the UBS Warburg 2008 Global Life Sciences Conference September 23

  9/19/2008

• Avant Immunotherapeutics CEO to Present at the 28th Annual Canaccord Adams Global Growth Conference

  8/11/2008

• Avant Immunotherapeutics to Report Second Quarter 2008 Financial Results on August 6, 2008

  8/4/2008

• 3M Drug Delivery Systems Collaborates with Avant Immunotherapeutics on Vaccine Adjuvants

  6/11/2008

• National Institutes of Health (NIH) Initiates Phase 1 Safety Study of Avant Immunotherapeutics's Oral Combined Enterotoxigenic E. coli-Cholera Vaccine

  6/4/2008

• Avant Immunotherapeutics CEO to Present at the Needham & Company Biotechnology & Medical Technology Conference

  6/4/2008

• Avant Immunotherapeutics Data Shows Brain Cancer Vaccine Doubles Survival

  6/3/2008

• Avant Immunotherapeutics Announces Oral Presentation of CDX-110 at ASCO Annual Meeting

  5/22/2008

• Avant Immunotherapeutics Announces Hart-Scott Rodino Clearance to License Cancer Vaccine to Pfizer Inc.

  5/21/2008

• Avant Immunotherapeutics Reports First Quarter 2008 Financial Results

  5/20/2008

• Avant Immunotherapeutics Announces Temporary Postponement of Conference Call

  5/19/2008

• Avant Immunotherapeutics to Report First Quarter 2008 Financial Results on May 19, 2008

  5/15/2008

• CEO and President Dr. Una Ryan Departs Avant Immunotherapeutics

  5/14/2008

• Avant Immunotherapeutics to Host Conference Call Today, April 16, 2008, at 5:00 PM to Discuss CDX-110 Partnership with Pfizer Inc.

  4/17/2008

• Avant Immunotherapeutics and Pfizer Inc. in Brain-Cancer Deal; Pfizer to Make Upfront Payment of $40M

  4/17/2008

• Significant Tumor-Specific Immune Response Observed in Avant Immunotherapeutics's Phase 2 Trial Evaluating CDX-110 with Temozolomide for Treatment of Glioblastoma Multiforme

  4/16/2008

• Avant Immunotherapeutics Resumes Trading under the Symbol ''AVAN''

  4/7/2008

• Avant Immunotherapeutics's Single-Dose Oral Ty800 Vaccine Meets Primary Endpoints in Phase 2 Study

  4/1/2008